Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21140748 | 0.88 | HRH3 (0.45) | MOGAT2HRH3TLR7TMEM97SIGMAR1 | |
| SCHEMBL26122391 | 0.83 | HRH3 (0.44) | MOGAT2HRH3TLR7TMEM97SIGMAR1 | |
| SCHEMBL21482067 | 0.83 | HRH3 (0.44) | MOGAT2HRH3TLR7TMEM97SIGMAR1 | |
| SCHEMBL23032967 | 0.83 | HRH3 (0.44) | MOGAT2HRH3TLR7TMEM97SIGMAR1 | |
| SCHEMBL28641279 | 0.83 | HRH3 (0.44) | MOGAT2HRH3TLR7TMEM97SIGMAR1 | |
| SCHEMBL26418968 | 0.81 | HRH3 (0.49) | MOGAT2HRH3TLR7TMEM97SIGMAR1 | |
| SCHEMBL22410358 | 0.77 | HRH3 (0.48) | MOGAT2HRH3TLR7TMEM97SIGMAR1 | |
| SCHEMBL26167807 | 0.77 | HRH3 (0.40) | MOGAT2HRH3TLR7KCNH2HSP90AA1 | |
| SCHEMBL19651524 | 0.77 | HRH3 (0.43) | MOGAT2HRH3TLR7TMEM97SIGMAR1 | |
| SCHEMBL22993389 | 0.77 | DRD2 (0.49) | HRH3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | MOGAT2 3868/4885HRH3 3081/4885TLR7 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.